YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression

Abstract Amyotrophic lateral sclerosis (ALS) has variable clinical course and fatal outcome. Since inflammation plays a role in the pathogenesis of ALS, chitinase-3-like protein 1 or YKL40 has been assessed as putative biomarker of disease progression. YKL40 mRNA levels are increased in anterior hor...

Full description

Bibliographic Details
Authors: Andrés Benito, Pol, Domínguez, Raúl, Colomina Soler, M. J. (María José), Llorens Torres, Franc, Povedano, Mònica, Ferrer, Isidro (Ferrer Abizanda)
Format: article
Status:Published version
Publication Date:2018
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/139899
Online Access:https://hdl.handle.net/2445/139899
Access Level:Open access
Keyword:Esclerosi lateral amiotròfica
Líquid cefalorraquidi
Medul·la espinal
Amyotrophic lateral sclerosis
Cerebrospinal fluid
Spinal cord
id ES_9745d037d1585a3e9a2b2a4e38c56d24
oai_identifier_str oai:diposit.ub.edu:2445/139899
network_acronym_str ES
network_name_str España
repository_id_str
spelling YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progressionAndrés Benito, PolDomínguez, RaúlColomina Soler, M. J. (María José)Llorens Torres, FrancPovedano, MònicaFerrer, Isidro (Ferrer Abizanda)Esclerosi lateral amiotròficaLíquid cefalorraquidiMedul·la espinalAmyotrophic lateral sclerosisCerebrospinal fluidSpinal cordAbstract Amyotrophic lateral sclerosis (ALS) has variable clinical course and fatal outcome. Since inflammation plays a role in the pathogenesis of ALS, chitinase-3-like protein 1 or YKL40 has been assessed as putative biomarker of disease progression. YKL40 mRNA levels are increased in anterior horn of the spinal cord (P=0.004) in sporadic ALS (sALS) cases when compared with age-matched controls. These correlate with increased mRNA expression of microglial markers AIF1 and CD68 in the spinal cord in sALS (P=0.044 and P=0.000, respectively). YKL40 mRNA and protein expression had a tendency to increase in post-mortem frontal cortex area 8 (P=0.06 and P=0.08, respectively). Yet YKL40 immunoreactivity is restricted to a subpopulation of astrocytes in these regions. YKL40 protein levels, as revealed by enzyme-linked immunosorbent assay (ELISA), are significantly increased in the CSF in sALS (n=86) compared with age-matched controls (n=21) (P=0.045). Higher levels are found in patients with fast progression when compared with patients with slow and normal progression (P=0.008 and P=0.004, respectively), and correlates with ALS-FRS-R slope (P=0.000). Additionally, increased protein levels of neurofilament light chain (NF-L) are also found in sALS (P=0.000); highest values are found in patients with fast progression when compared with cases with slow and normal progression (P=0.005 and P=0.000, respectively), and also correlate with ALS-FRS-R slope (P=0.000). Pearson's correlation test linked positively the increased levels of YKL40 with increased NF-L levels (P=0.013). These data point to YKL40 and NF-L protein levels in the CSF as a good biomarker combination of disease progression in sALS.Impact Journals2018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/139899Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.18632/aging.101551Aging, 2018, vol. 10, num. 9, p. 2367-2382https://doi.org/10.18632/aging.101551cc-by (c) Andrés Benito, Pol et al., 2018http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1398992026-05-27T06:46:51Z
dc.title.none.fl_str_mv YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
title YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
spellingShingle YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
Andrés Benito, Pol
Esclerosi lateral amiotròfica
Líquid cefalorraquidi
Medul·la espinal
Amyotrophic lateral sclerosis
Cerebrospinal fluid
Spinal cord
title_short YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
title_full YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
title_fullStr YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
title_full_unstemmed YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
title_sort YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression
dc.creator.none.fl_str_mv Andrés Benito, Pol
Domínguez, Raúl
Colomina Soler, M. J. (María José)
Llorens Torres, Franc
Povedano, Mònica
Ferrer, Isidro (Ferrer Abizanda)
author Andrés Benito, Pol
author_facet Andrés Benito, Pol
Domínguez, Raúl
Colomina Soler, M. J. (María José)
Llorens Torres, Franc
Povedano, Mònica
Ferrer, Isidro (Ferrer Abizanda)
author_role author
author2 Domínguez, Raúl
Colomina Soler, M. J. (María José)
Llorens Torres, Franc
Povedano, Mònica
Ferrer, Isidro (Ferrer Abizanda)
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Esclerosi lateral amiotròfica
Líquid cefalorraquidi
Medul·la espinal
Amyotrophic lateral sclerosis
Cerebrospinal fluid
Spinal cord
topic Esclerosi lateral amiotròfica
Líquid cefalorraquidi
Medul·la espinal
Amyotrophic lateral sclerosis
Cerebrospinal fluid
Spinal cord
description Abstract Amyotrophic lateral sclerosis (ALS) has variable clinical course and fatal outcome. Since inflammation plays a role in the pathogenesis of ALS, chitinase-3-like protein 1 or YKL40 has been assessed as putative biomarker of disease progression. YKL40 mRNA levels are increased in anterior horn of the spinal cord (P=0.004) in sporadic ALS (sALS) cases when compared with age-matched controls. These correlate with increased mRNA expression of microglial markers AIF1 and CD68 in the spinal cord in sALS (P=0.044 and P=0.000, respectively). YKL40 mRNA and protein expression had a tendency to increase in post-mortem frontal cortex area 8 (P=0.06 and P=0.08, respectively). Yet YKL40 immunoreactivity is restricted to a subpopulation of astrocytes in these regions. YKL40 protein levels, as revealed by enzyme-linked immunosorbent assay (ELISA), are significantly increased in the CSF in sALS (n=86) compared with age-matched controls (n=21) (P=0.045). Higher levels are found in patients with fast progression when compared with patients with slow and normal progression (P=0.008 and P=0.004, respectively), and correlates with ALS-FRS-R slope (P=0.000). Additionally, increased protein levels of neurofilament light chain (NF-L) are also found in sALS (P=0.000); highest values are found in patients with fast progression when compared with cases with slow and normal progression (P=0.005 and P=0.000, respectively), and also correlate with ALS-FRS-R slope (P=0.000). Pearson's correlation test linked positively the increased levels of YKL40 with increased NF-L levels (P=0.013). These data point to YKL40 and NF-L protein levels in the CSF as a good biomarker combination of disease progression in sALS.
publishDate 2018
dc.date.none.fl_str_mv 2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/139899
url https://hdl.handle.net/2445/139899
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.18632/aging.101551
Aging, 2018, vol. 10, num. 9, p. 2367-2382
https://doi.org/10.18632/aging.101551
dc.rights.none.fl_str_mv cc-by (c) Andrés Benito, Pol et al., 2018
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Andrés Benito, Pol et al., 2018
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Impact Journals
publisher.none.fl_str_mv Impact Journals
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414049784004608
score 15,301603

Similar Items